contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


herantis-pharma-participating-at-sachs-nordic-life-science-days-and-finnish-investor-conferences-in-august-and-september

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Herantis Pharma

Press releaseHerantis Pharma Plc, Press Release 28 August 2024 at 09:00 EESTHerantis Pharma participating at Sachs, Nordic Life Science days and Finnish investor conferences in August and SeptemberHer...

Press releaseHerantis Pharma Plc, Press Release 28 August 2024 at 09:00 EESTHerantis Pharma participating at Sachs, Nordic Life Science days and Finnish investor conferences in August and SeptemberHerantis Pharma Plc (“Herantis”),&nbsp;a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease is pleased to announce that Herantis management will participate at the following conferences:<ul><li>August 28th: Nasdaq Helsinki Stock Exchange’s Open Doors (Pörssin Avoimet Ovet 2024), Helsinki, Finland Herantis presentation at 17.10 EEST</li></ul><ul><li>September 10th: Stock market investor’s week 2024 (Inderes) – Healthcare, Helsinki, Finland Herantis presentation at 13.40 EEST</li></ul><ul><li>September 17-19th: Nordic Life Science Days, Malmö, Sweden Herantis presentation at 11.15 CEST, September 18th.</li></ul><ul><li>September 25-26th: Sachs – 24th Annual Biotech in Europe Forum for global partnering &amp; investment, Basel, Switzerland.&nbsp;Herantis company presentation will be held on September 25th. Antti Vuolanto, CEO will participate in the&nbsp;Sachs Neurological Disorders Panel: Rapid Advances with New Targets &amp; Modalities. Co-Chaired by: Hugh Nuthall, Executive Director, Search &amp; Evaluation Neuroscience, Eli Lilly and Company, and Keld Flintholm Jørgensen, Executive VP &amp; CBO, H. Lundbeck A/S on September 25th at 17.10 CEST</li></ul>If you want to schedule a meeting with us, please send an email to:&nbsp;<a href="mailto:ir@herantis.com">ir@herantis.com</a>.For more information, please contact:Tone Kvåle, CFOTel: +47 915 19576Email:&nbsp;<a href="mailto:ir@herantis.com">ir@herantis.com</a>Certified Advisor:UB Corporate Finance LtdTel: +358 9 25 380&nbsp;225Email: <a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>About Herantis Pharma PlcHerantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.Company website:&nbsp;<a href="http://www.herantis.com/">www.herantis.com</a>

Herantis Pharma participating at Sachs, Nordic Life Science days and Finnish investor conferences in August and September

Stay up to date with our newsletter